|
|
News Breaks | | | | September 28, 2012 | | 07:25 EDT |  | APRI, APRI | Apricus Biosciences management to meet with Lazard Capital
Meeting to be held in London on October 5 hosted by Lazard Capital. | |
|
News For APRI From The Last 14 Days Check below for free stories on APRI the last two weeks. |
|
|
| June 10, 2013 | | 10:57 EDT | | APRI | Apricus Biosciences held a conference call
 Subscribe for More Information | | | 09:28 EDT |  | APRI | On The Fly: Pre-market Movers
HIGHER: Monsanto (MON), up 3.5% after Monsanto following upgrade at Macquarie, comments from Morgan Stanley on implications of potential approval of product in China... Facebook (FB), up 3.1% following upgrade at Stifel, JPMorgan reiterating its Overweight rating on shares... Apricus Biosciences (APRI), up 14% after announcing European approval for ED drug Vitaros... McDonalds (MCD), up 1.8% after May global comp sales rose 2.6%. LOWER: Tesla (TSLA), down 3.2% following cautious mention over weekend in Barron's magazine... Titan International (TWI), down 5.8% following downgrades by at least three firms... Dynavax (DVAX), down 29% after reporting feedback from FDA meeting regarding Heplisav. | | | 07:10 EDT | | APRI | Apricus Biosciences receives European approval for Vitaros
Apricus Biosciences announced that its marketing application for Vitaros, indicated for the treatment of patients with erectile dysfunction, has been approved through the European Decentralized Procedure. Under the DCP, Apricus Bio filed its application for marketing approval designating Netherlands as the Reference Member State on behalf of nine other European Concerned Member States participating in the procedure. | |
|
|
|
|
|
|
